Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00334828 · ClinicalTrials.gov registry record · Phase 3
ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis
A Phase 3 study of Severe Sepsis, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,000
- Enrollment target
- 20
- Study locations
NCT00334828: Completed Phase 3 study of Severe Sepsis, sponsored by Eisai.
NCT00334828 is a Phase 3 study of Severe Sepsis that has completed, run by Eisai. The registered enrollment target is 2,000 participants, below the 5,989-participant average among 9 other Severe Sepsis trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00334828, a Phase 3 study of Severe Sepsis, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare eritoran tetrasodium and placebo in patients with severe sepsis and to demonstrate a reduction of mortality from all causes.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG eritoran tetrasodium
Study Locations (20)
Florida
- - Atlantis
- - Clearwater
- - Gainesville
- - Miami
- - Orlando
- - Pensacola
California
- - Loma Linda
- - Marysville
- - Orange
- - San Diego
- - Santa Barbara
Alabama
- - Birmingham
- - Mobile
Georgia
- - Atlanta
- - Decatur
Arizona
- - Mesa
Colorado
- - Denver
Connecticut
- - New Haven
Delaware
- - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2006-06 |
| Phase | Phase 3 |
What the finished NCT00334828 record still lists
NCT00334828 is an interventional study that assigns participants to a tested intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, below the 5,989-participant average among 9 other Severe Sepsis trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Severe Sepsis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00334828 names 20 study sites across 9 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT00334828 about?
NCT00334828 is a clinical study titled "ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis". The purpose of this study is to compare eritoran tetrasodium and placebo in patients with severe sepsis and to demonstrate a reduction of mortality from all causes.
What is the current status of trial NCT00334828?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,000 participants. The study started on 2006-06.
What conditions does trial NCT00334828 study?
This clinical trial studies the following conditions: Severe Sepsis.
What interventions are being tested in trial NCT00334828?
The interventions under investigation include: Placebo (DRUG), eritoran tetrasodium (DRUG).
Who is sponsoring clinical trial NCT00334828?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00334828 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00334828's enrollment target sits among peer trials
2,000 3rd of 9 higher than 7 of 9 other Severe Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Severe Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zinc Therapy in Critical Illness
ACTIVE NOT RECRUITING · Phase 1
-
Monocyte Distribution Width (MDW) in the General Population of Emergency Department Patients With and Without Bacteremia
ACTIVE NOT RECRUITING
-
A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.
COMPLETED · Phase 1
-
Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock
COMPLETED
-
Predictive algoRithm for EValuation and Intervention in SEpsis
COMPLETED · NA
-
Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia